Literature DB >> 8735638

Inhibition of glycolysis and enhanced mechanical function of working rat hearts as a result of adenosine A1 receptor stimulation during reperfusion following ischaemia.

B A Finegan1, G D Lopaschuk, M Gandhi, A S Clanachan.   

Abstract

1. This study examined effects of adenosine and selective adenosine A1 and A2 receptor agonists on glucose metabolism in rat isolated working hearts perfused under aerobic conditions and during reperfusion after 35 min of global no-flow ischaemia. 2. Hearts were perfused with a modified Krebs-Henseleit buffer containing 1.25 mM Ca2+, 11 mM glucose, 1.2 mM palmitate and insulin (100 muu ml-1), and paced at 280 beats min-1. Rates of glycolysis and glucose oxidation were measured from the quantitative production of 3H2O and 14CO2, respectively, from [5-3H/U-14C]-glucose. 3. Under aerobic conditions, adenosine (100 microM) and the adenosine A1 receptor agonist, N6-cyclohexyladenosine (CHA, 0.05 microM), inhibited glycolysis but had no effect on either glucose oxidation or mechanical function (as assessed by heart rate systolic pressure product). The improved coupling of glycolysis to glucose oxidation reduced the calculated rate of proton production from glucose metabolism. The adenosine A1 receptor antagonist, 8-cyclopentyl-1,3-dipropylxanthine (DPCPX 0.3 microM) did not alter glycolysis or glucose oxidation per se but completely antagonized the adenosine- and CHA-induced inhibition of glycolysis and proton production. 4. During aerobic reperfusion following ischaemia, CHA (0.05 microM) again inhibited glycolysis and proton production from glucose metabolism and had no effect on glucose oxidation. CHA also significantly enhanced the recovery of mechanical function. In contrast, the selective adenosine A2a receptor agonist, CGS-21680 (1.0 microM), exerted no metabolic or mechanical effects. Similar profiles of action were seen if these agonists were present during ischaemia and throughout reperfusion or when they were present only during reperfusion. 5. DPCPX (0.3 microM), added at reperfusion, antagonized the CHA-induced improvement in mechanical function. It also significantly depressed the recovery of mechanical function per se during reperfusion. Both the metabolic and mechanical effects of adenosine (100 microM) were antagonized by the nonselective A1/A2 antagonist, 8-sulphophenyltheophylline (100 microM). 6. These data demonstrate that inhibition of glycolysis and improved recovery of mechanical function during reperfusion of rat isolated hearts are mediated by an adenosine A1 receptor mechanism. Improved coupling of glycolysis and glucose oxidation during reperfusion may contribute to the enhanced recovery of mechanical function by decreasing proton production from glucose metabolism and the potential for intracellular Ca2+ accumulation, which if not corrected leads to mechanical dysfunction of the postischaemic myocardium.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8735638      PMCID: PMC1909613          DOI: 10.1111/j.1476-5381.1996.tb15410.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  39 in total

Review 1.  Protective effects of ATP sensitive potassium channel openers in models of myocardial ischaemia.

Authors:  G J Grover
Journal:  Cardiovasc Res       Date:  1994-06       Impact factor: 10.787

2.  Protection from ischaemic-reperfusion injury with adenosine pretreatment is reversed by inhibition of ATP sensitive potassium channels.

Authors:  C F Toombs; D S McGee; W E Johnston; J Vinten-Johansen
Journal:  Cardiovasc Res       Date:  1993-04       Impact factor: 10.787

3.  Adenosine inhibits exocytotic release of endogenous noradrenaline in rat heart: a protective mechanism in early myocardial ischemia.

Authors:  G Richardt; W Waas; R Kranzhöfer; E Mayer; A Schömig
Journal:  Circ Res       Date:  1987-07       Impact factor: 17.367

4.  Adenosine and insulin mediate glucose uptake in normoxic rat hearts by different mechanisms.

Authors:  D A Angello; R M Berne; N M Coddington
Journal:  Am J Physiol       Date:  1993-09

5.  Receptor-mediated cardioprotective effects of endogenous adenosine are exerted primarily during reperfusion after coronary occlusion in the rabbit.

Authors:  Z Q Zhao; S McGee; K Nakanishi; C F Toombs; W E Johnston; M S Ashar; J Vinten-Johansen
Journal:  Circulation       Date:  1993-08       Impact factor: 29.690

6.  Adenosine protects ischemic and reperfused myocardium by receptor-mediated mechanisms.

Authors:  M F Janier; J L Vanoverschelde; S R Bergmann
Journal:  Am J Physiol       Date:  1993-01

7.  Adenosine increases lactate release and delays onset of contracture during global low flow ischaemia.

Authors:  R D Lasley; R M Mentzer
Journal:  Cardiovasc Res       Date:  1993-01       Impact factor: 10.787

8.  Plasma fatty acid levels in infants and adults after myocardial ischemia.

Authors:  G D Lopaschuk; R Collins-Nakai; P M Olley; T J Montague; G McNeil; M Gayle; P Penkoske; B A Finegan
Journal:  Am Heart J       Date:  1994-07       Impact factor: 4.749

9.  A1 receptor mediated myocardial infarct size reduction by endogenous adenosine is exerted primarily during ischaemia.

Authors:  Z Q Zhao; K Nakanishi; D S McGee; P Tan; J Vinten-Johansen
Journal:  Cardiovasc Res       Date:  1994-02       Impact factor: 10.787

10.  Evidence that the adenosine A3 receptor may mediate the protection afforded by preconditioning in the isolated rabbit heart.

Authors:  G S Liu; S C Richards; R A Olsson; K Mullane; R S Walsh; J M Downey
Journal:  Cardiovasc Res       Date:  1994-07       Impact factor: 10.787

View more
  11 in total

1.  Tolerance to ischaemic injury in remodelled mouse hearts: less ischaemic glycogenolysis and preserved metabolic efficiency.

Authors:  Waleed G T Masoud; Osama Abo Al-Rob; Yang Yang; Gary D Lopaschuk; Alexander S Clanachan
Journal:  Cardiovasc Res       Date:  2015-07-06       Impact factor: 10.787

Review 2.  Cardiac purinergic signalling in health and disease.

Authors:  Geoffrey Burnstock; Amir Pelleg
Journal:  Purinergic Signal       Date:  2014-12-20       Impact factor: 3.765

3.  Transgenic A1 adenosine receptor overexpression increases myocardial resistance to ischemia.

Authors:  G P Matherne; J Linden; A M Byford; N S Gauthier; J P Headrick
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-10       Impact factor: 11.205

4.  Adenosine A₂A and A₂B receptors are both required for adenosine A₁ receptor-mediated cardioprotection.

Authors:  Enbo Zhan; Victoria J McIntosh; Robert D Lasley
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-07-08       Impact factor: 4.733

5.  Alteration of glycogen and glucose metabolism in ischaemic and post-ischaemic working rat hearts by adenosine A1 receptor stimulation.

Authors:  H Fraser; G D Lopaschuk; A S Clanachan
Journal:  Br J Pharmacol       Date:  1999-09       Impact factor: 8.739

6.  Partial adenosine A1 receptor agonists for cardiovascular therapies.

Authors:  Barbara E Albrecht-Küpper; Kirsten Leineweber; Peter G Nell
Journal:  Purinergic Signal       Date:  2011-11-12       Impact factor: 3.765

7.  Modulation of cardiac A1-adenosine receptors in rats following treatment with agents affecting heart rate.

Authors:  Nissim Balas; Michael Arad; Babeth Rabinowitz; Asher Shainberg
Journal:  Mol Cell Biochem       Date:  2002-02       Impact factor: 3.396

8.  Oxidant stress and damage in post-ischemic mouse hearts: effects of adenosine.

Authors:  Benjamin Hack; Paul K Witting; Benjamin S Rayner; Roland Stocker; John P Headrick
Journal:  Mol Cell Biochem       Date:  2006-05-23       Impact factor: 3.396

9.  Influence of beta-adrenoceptor tone on the cardioprotective efficacy of adenosine A(1) receptor activation in isolated working rat hearts.

Authors:  W R Ford; B I Jugdutt; G D Lopaschuk; R Schulz; A S Clanachan
Journal:  Br J Pharmacol       Date:  2000-10       Impact factor: 8.739

10.  Contractile effects of adenosine, coronary flow and perfusion pressure in murine myocardium.

Authors:  Laura Willems; John P Headrick
Journal:  Pflugers Arch       Date:  2006-10-28       Impact factor: 3.657

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.